The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Secondary chemoprevention using short period (3 months) of LHRHa as an option for men with low-risk localized prostate cancer (LRPC) before active surveillance (AS).
Olivier Cussenot
No relevant relationships to disclose
Sarah Drouin
No relevant relationships to disclose
Christophe Egrot
No relevant relationships to disclose
Jean-Nicolas Cornu
No relevant relationships to disclose
Philippe Sebe
No relevant relationships to disclose
Pierre Mozer
No relevant relationships to disclose
Pierre Conort
No relevant relationships to disclose
Christophe Vaessen
No relevant relationships to disclose
Francois Haab
No relevant relationships to disclose
Marc-Olivier Bitker
No relevant relationships to disclose
Morgan Roupret
No relevant relationships to disclose